Where Progress Lives: This Month in California Life Sciences October 2026

Key Takeaways
  • A new report from the Biotechnology Innovation Organization (BIO), the Council of State Bioscience Associations (CSBA), and TEConomy Partners confirmed California as the nation’s largest bioscience employer, supporting over 334,000 industry jobs across nearly 16,000 life sciences businesses that call California home.
  • At the European Society for Medical Oncology (ESMO) Congress 2026, CLS member companies presented new data against some of the hardest-to-treat cancers, including an Amgen and AstraZeneca combination that reduced the risk of death by 58% in extensive-stage small cell lung cancer and a Genentech therapy that outperformed approved treatments in head-to-head testing.
  • Five innovations from CLS member companies were named to TIME’s Best Inventions of 2026, and CLS announced its 2026 Pantheon Award honorees, from Genentech’s 50 years of pioneering science to Revolution Medicines’ RASONQUE™.
  • CLS brought free care to farmworker families in Monterey County and joined Assemblymember Mia Bonta to convene life sciences leaders in Alameda County on what it takes for businesses to start, scale, and stay in California.

Each month, California Life Sciences (CLS) President and CEO Mike Guerra shares what’s shaping the life sciences industry, highlights the conversations that matter most to members, and offers a window into what the CLS team is working on.

Last month, I wrote about the full reach of California’s life sciences ecosystem, from students discovering science for the first time to families receiving the first treatments ever approved for their diseases. In October, the rest of the world took stock of what that ecosystem produces. New national data measured the economic footprint of our industry state by state, and California led. At the European Society for Medical Oncology (ESMO) Congress in Madrid, therapies discovered and developed by California companies delivered some of the most anticipated results of the meeting, including two presented in its Presidential Symposium. TIME recognized our members’ breakthroughs among the best inventions of the year, and we announced the honorees we will celebrate at this year’s Pantheon Awards. Each of these moments points back to the same place, and to the patients counting on what comes out of it.

California’s Bioscience Economy Leads the Nation

On October 28, 2026, BIO and CSBA, which I am proud to chair, released the 12th edition of the BIO-TEConomy report, The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions. Produced with TEConomy Partners, the report measures the industry’s national and state-level economic footprint through employment, wages, business establishments, university research and development, access to capital, and other measures.

California continues to lead the U.S. innovation economy. Our state is the nation’s largest bioscience employer, with more than 334,000 industry jobs across almost 16,000 life sciences businesses, and our industry employment is 25% above the national average. But that leadership is not guaranteed. It can only be sustained through smart policy and consistent funding.

As China aggressively invests in biotechnology, Congress and the California Legislature continue to advance policies that discourage domestic investment in our industry and make it harder for American innovators to compete. We cannot afford to undermine our own competitive advantage while China works to surpass us. Our government must support the research and innovation happening right here at home. If not, America’s foreign adversaries will.

California Science on the World Stage

The ESMO Congress is one of the most important venues in the world for new cancer data, and this year, CLS members were at the center of it. The trials behind these results enrolled patients around the globe, but the science at their core was discovered and built here in California. Madrid was simply where the world gathered to see it.

Amgen, based in Thousand Oaks, delivered one of the congress’s defining results. In the Phase 3 DeLLphi-305 trial, IMDELLTRA® combined with AstraZeneca’s IMFINZI® reduced the risk of death by 58% as a first-line maintenance treatment for extensive-stage small cell lung cancer, extending the median overall survival beyond 21 months. Small cell lung cancer is one of the most aggressive solid tumors, and patients have typically survived about a year from the start of first-line maintenance treatment. The results were presented in ESMO’s Presidential Symposium and published simultaneously in The New England Journal of Medicine.

For decades, researchers considered the RAS family of proteins undruggable. In Madrid, three California companies showed how far that science has come. From the South San Francisco campus where biotech began 50 years ago, Genentech presented results from the Phase 3 Krascendo 1 trial, the first global study to compare a next-generation KRAS G12C inhibitor directly against the first-generation treatments. Divarasib improved both progression-free and overall survival for patients with previously treated KRAS G12C-mutated non-small cell lung cancer, results the trial’s lead investigator says establish a new standard of care. Redwood City-based Revolution Medicines presented new analyses from its Phase 3 RASolute 302 trial showing that RASONQUE™ (daraxonrasib), approved in August for previously treated metastatic pancreatic cancer, delivered a consistent overall survival benefit across the RAS genotype subgroups evaluated. And South San Francisco’s Frontier Medicines shared first clinical data for FMC-376, which shrank tumors in 56% of evaluable patients with KRAS G12C-mutant lung cancer, including patients whose cancer had already been treated with existing inhibitors.

The pipeline behind those results runs deep. ORIC Pharmaceuticals, with offices in South San Francisco and San Diego, presented an 84% confirmed response rate for enozertinib as a first-line treatment for non-small cell lung cancer driven by atypical EGFR mutations, and plans to advance the drug into a global Phase 3 trial in the first half of 2027. San Diego’s Iambic, which filed to go public last month, presented updated data for IAM1363, its AI-designed treatment for HER2-driven cancers, showing durable responses in patients who had already been through multiple lines of therapy.

Each of these results represents years of work by scientists in our state, and for patients whose options have been limited, they represent something more important: the possibility of more time. When California science leads on a global stage, it is a reminder of exactly what this ecosystem exists to produce.

Recognizing What Is Made in California

In October, TIME released its Best Inventions of 2026, and several CLS members’ transformative discoveries were honored. Revolution Medicines’ RASONQUE™ (daraxonrasib) was recognized for its impact on pancreatic cancer, one of the deadliest diagnoses in oncology. It was joined by Takeda’s ORZEYFUL™, approved in August as the first medicine designed to treat the underlying cause of narcolepsy type 1, and ICOTYDE®, developed by Johnson & Johnson and Bay Area-based Protagonist Therapeutics as the first targeted oral peptide to block the IL-23 receptor in plaque psoriasis. San Jose-based Visby Medical was recognized for its rapid at-home PCR test for women’s sexually transmitted infections, which delivers results in about 30 minutes, and Merck was recognized for Lipfendra, the first FDA-approved oral PCSK9 inhibitor for lowering LDL cholesterol.

Closer to home, on October 8 we announced the winners and finalists of the 23rd Annual Pantheon Awards. This year’s honorees span the full life of our industry. Genentech will receive the Industry Pioneer Award, 50 years after it launched biotechnology in South San Francisco. Catriona Jamieson, MD, PhD, Director of the Sanford Stem Cell Institute at UC San Diego, will receive our Leadership Award for research into cancer stem cells that is reshaping how leukemia and related disorders are treated. Ziad Obermeyer, MD, Associate Professor and Blue Cross of California Distinguished Professor at UC Berkeley, will receive our Academic Discovery of the Year Award for developing an AI model that reads electrocardiograms to identify people at risk of sudden cardiac death. Revolution Medicines’ RASONQUE™ (daraxonrasib) will be honored as our Biopharma Product of the Year, and it means a great deal to recognize RevMed in the same year its science reached patients facing one of medicine’s hardest diagnoses. Rounding out this year’s winners, Teal Health will receive Convergent Technology of the Year for the Teal Wand, Noetik will be named our AI Catalyst for Health, and San Diego Squared will receive the Elizabeth Schar Inspiring Future Leaders Award.

We will also celebrate our five Emerging Innovator of the Year finalists: Character Biosciences, Cyclarity Therapeutics, Iolyx Therapeutics, Profluent, and Samay. The winner will be announced live in San Francisco on November 12.

Meeting Communities Where They Are

The strength of California’s ecosystem depends on the communities it serves and on a policy environment that lets companies grow here, and October brought both into focus.

Earlier in October, California Life Sciences and Assemblymember Mia Bonta convened an Alameda Life Sciences Roundtable to dive into what it takes for a business to successfully start, scale, and stay in California. Our group was hosted by Penumbra, Inc., Alameda’s largest employer, with about 1,850 local jobs. They are a clear example of what’s possible when medtech innovators can grow close to home. The discussion was centered around how we keep growing this ecosystem through support at the local and state level, the pivotal nature of access to capital for startups, and the need for a strong local workforce.

On October 25, we hosted our annual Farmworker Health & Wellness Event in Monterey County. Farmworkers are the backbone of our state, and it was an honor to bring free care directly to them, all in one place. Alongside leaders who continually show up for our farmworker community, we served hundreds of families. We’re grateful to the Office of Senator John Laird, the Office of Speaker Robert Rivas, Monterey County Supervisor Lusi Alejo, Salinas Mayor Dennis Donohue, Salinas Councilmember José Luis Barajas, Salinas Councilmember Margaret D’Arrigo, Soledad Mayor Anna Velazquez, Consulado General de México en San José, Consul General Neftali Said Pérez Gónzález, and all of our partners for making this day possible.

Looking Ahead

October showed California’s life sciences ecosystem from every angle. The numbers confirmed that our state leads the nation in the people, research, and capital that drive this industry. The science, presented on a global stage, showed what that leadership produces for patients facing some of the hardest diagnoses in medicine. And the recognition, from TIME to our own Pantheon honorees, reflected how much of our industry’s progress continues to start here. Sustaining that leadership takes the same deliberate effort that built it.

On November 12, we will gather at the Westin St. Francis in San Francisco to celebrate the 23rd Annual Pantheon Awards under this year’s theme, Made in California. It is a fitting description of the month we just had.

I am grateful for the colleagues and partners who make all of this possible, and I look forward to sharing more next month.

Mike Guerra is President and CEO of California Life Sciences (CLS), California’s most influential life sciences trade association, representing more than 1,300 member companies. He chairs the Council of State Bioscience Associations and sits on multiple industry boards, working to advance California’s position as the world’s leading life sciences innovation ecosystem. Mike champions effective public policy at the national, state, and local levels, and is a steadfast advocate for the entrepreneurs and businesses driving life sciences forward in California.